MedCity News April 14, 2025
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is stopping development of its drug, danuglipron, after a liver complication emerged in a clinical trial.
The pharmaceutical giant was evaluating danuglipron in two Phase 1 dose-optimization studies. The company said Monday a patient in one of those studies experienced a potential drug-induced liver injury. This...
Today's Sponsors
Today's Sponsor